• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Beyond Air Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Other Events, Financial Statements and Exhibits

    12/30/25 5:00:49 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care
    Get the next $XAIR alert in real time by email
    false 0001641631 0001641631 2025-12-26 2025-12-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): December 26, 2025

     

    Beyond Air, Inc.

    (Exact Name of Registrant as Specified in Charter)

     

    Delaware   001-38892   47-3812456

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    900 Stewart Avenue, Suite 301

    Garden City, NY 11530

    (Address of Principal Executive Offices and Zip Code)

     

    (516) 665-8200

    Registrant’s Telephone Number, Including Area Code

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $.0001 per share   XAIR   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     
     

     

    Item 1.01. Material Agreement

     

    The disclosure in relation to the employment agreement included in Item 5.02 of this Current Report on Form 8-K, is incorporated by reference herein into this Item 1.01, as applicable.

     

    Item 5.02. Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers.

     

    On December 24, 2025, the Board of Directors of Beyond Air, Inc. (the “Company”) approved the appointment of Daniel Moorhead as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective as of January 5, 2026 (the “Effective Date”). Mr. Moorhead will replace Denton “Duke” Dewrell as the Company’s principal financial officer and principal accounting officer as of the Effective Date. Mr. Dewrell had temporarily assumed the role and responsibility of the principal financial officer and principal accounting officer of the Company, and will remain employed by the Company as its controller.

     

    Mr. Moorhead, age 53, most recently served as the Chief Financial Officer of Zynex, Inc. from June 2017 to August 2025. Prior to his role with Zynex, Mr. Moorhead previously served as Chief Financial Officer of Evolving Systems, Inc. (Nasdaq: EVOL) from January 2016 until May 2017, after having served as Vice President of Finance & Administration from December 2011 through December 2015 and in other financial management roles from 2002-2005 and 2008-2011. Mr. Moorhead is a CPA and holds a B.B.A. in Accounting from the University of Northern Colorado.

     

    There are no arrangements or understandings between Mr. Moorhead and any other person pursuant to which he was selected as an officer of the Company, and there is no family relationship between Mr. Moorhead and any of the Company’s other directors or executive officers. There are no related party transactions between Mr. Moorhead and the Company that would require disclosure under Item 404(a) of Regulation S-K.

     

    In connection with Mr. Moorhead’s appointment, the Company and Mr. Moorhead entered into an Employment Agreement, effective December 25, 2025 (“Employment Agreement”). Pursuant to the Employment Agreement, Mr. Moorhead’s annual salary will be $325,000 and he will be eligible for a discretionary bonus and to participate in the Eighth Amended and Restated 2013 Equity Incentive Plan (the “Plan”). In addition, Mr. Moorhead was granted an employment inducement stock option award exercisable for the purchase of 70,000 shares of the Company’s Common Stock, subject to the terms of the Plan, and the applicable award agreement to be entered into by and between the Company and Mr. Moorhead. The stock option will vest 25% on the first anniversary and annually thereafter in 3 equal installments, provided that, no portion of the stock option that is not exercisable at the time of termination of employment for any reason shall thereafter become exercisable.

     

    The foregoing description of the Employment Agreement is not complete and is qualified in its entirety by reference to the Employment Agreement, which is filed as exhibit 10.1 to this Current Report on Form 8-K.

     

    Item 8.01. Other Events

     

    On December 30, 2025, the Company issued a press release announcing the appointment of Mr. Moorhead as Chief Financial Officer. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description
    10.1   Employment Agreement, by and between the Company and Daniel Moorhead
    99.1   Press Release of Beyond Air, Inc., dated as of December 30, 2025.
    104   Cover Page Interactive Data File (embedded within the inline XBRL document).

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      BEYOND AIR, Inc.
       
    Date: December 30, 2025 By: /s/ Steven A. Lisi
      Name: Steven A. Lisi
      Title Chief Executive Officer

     

     

    Get the next $XAIR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XAIR

    DatePrice TargetRatingAnalyst
    7/17/2025$11.00Buy
    D. Boral Capital
    6/25/2024Buy → Neutral
    BTIG Research
    7/28/2023$10.00Overweight
    Piper Sandler
    6/15/2023$15.00Buy
    BTIG Research
    11/12/2021$12.00 → $16.00Buy
    Truist Securities
    More analyst ratings

    $XAIR
    SEC Filings

    View All

    Beyond Air Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - Beyond Air, Inc. (0001641631) (Filer)

    12/30/25 5:00:49 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form DEF 14A filed by Beyond Air Inc.

    DEF 14A - Beyond Air, Inc. (0001641631) (Filer)

    12/19/25 4:15:50 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form 424B3 filed by Beyond Air Inc.

    424B3 - Beyond Air, Inc. (0001641631) (Filer)

    12/16/25 8:15:24 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer's Disease and Reinforcing Platform's Strength Across Neurological Disorders

    BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company developing transformative treatments for complex neurological disorders, including Autism Spectrum Disorder (ASD), brain cancers, and Alzheimer's disease, and a subsidiary of Beyond Air (NASDAQ:XAIR), proudly announces the publication of breakthrough research by its Chief Scientific Officer, Prof. Haitham Amal, in Translational Psychiatry, a peer-reviewed medical journal published by Nature Publishing Group. The article, which is titled, "Shared Early Molecular Mechanisms Revealed in P301S and 5xFAD Alzheimer's Disease Mouse Models," presents compelling evidence of a novel mechanism in the early sta

    4/1/25 8:00:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy

    First-in-human studies anticipated to begin in 2026 Engaged a top tier U.S. based contract manufacturer to ensure the highest standards of quality Currently in the advanced stages of formulation development for subcutaneous injection, with plans for an oral formulation BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and other complex neurological conditions, including Alzheimer's disease and brain cancers, and a subsidiary of Beyond Air (NASDAQ:XAIR), has secured an initial $2 million in equity financing from private investors as part of a larger funding round.

    3/24/25 4:05:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy

    The Phase 1b study will evaluate LV UNO in unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic solid tumor cancer patients that have progressed or have prolonged stable disease on single agent PD-1 inhibitorsThe primary objective of the Phase 1b study is to assess preliminary efficacy by objective response rate (ORR) and duration of response (DOR) per RECIST version 1.1 and secondarily immune-related response via iRECISTThe study will recruit patients from four sites across Israel HAMILTON, Bermuda, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical-stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an imm

    12/3/24 4:05:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    D. Boral Capital initiated coverage on Beyond Air with a new price target

    D. Boral Capital initiated coverage of Beyond Air with a rating of Buy and set a new price target of $11.00

    7/17/25 8:02:31 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air downgraded by BTIG Research

    BTIG Research downgraded Beyond Air from Buy to Neutral

    6/25/24 8:04:46 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Piper Sandler initiated coverage on Beyond Air with a new price target

    Piper Sandler initiated coverage of Beyond Air with a rating of Overweight and set a new price target of $10.00

    7/28/23 7:37:57 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and Chairman of the Board Lisi Steven A. bought $19,491 worth of shares (6,000 units at $3.25), increasing direct ownership by 0.18% to 3,327,411 units (SEC Form 4)

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    7/23/25 4:05:39 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Director Carey Robert bought $250,050 worth of shares (1,000,000 units at $0.25), increasing direct ownership by 33% to 4,076,864 units (SEC Form 4)

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    3/17/25 8:15:33 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Chief Operating Officer Gaul Michael A. bought $2,294 worth of shares (6,000 units at $0.38), increasing direct ownership by 7% to 94,150 units (SEC Form 4)

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    2/21/25 5:00:14 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Moorhead Daniel J

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    1/6/26 4:17:51 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Moorhead Daniel J

    3 - Beyond Air, Inc. (0001641631) (Issuer)

    1/6/26 4:15:38 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Lee Yoori

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    11/24/25 5:22:10 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 1, 2022 - FDA Roundup: July 1, 2022

    For Immediate Release: July 01, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a request for nominations for consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. The FDA relies on our many advisory committees to help us

    7/1/22 11:54:25 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Leadership Updates

    Live Leadership Updates

    View All

    Beyond Cancer™ Announces the Appointment of Jedidiah Monson, M.D. to Chief Medical Officer

    Dr. Monson is a board-certified radiation oncologist and brings over 25 years of clinical oncology experience to Beyond Cancer. Dr. Monson is a founding partner and President of California Cancer Associates for Research & Excellence (cCARE), the largest private oncology practice in California. HAMILTON, Bermuda, June 01, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ:XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced the appointment of Jedidiah Monson, M.D. to the position of Chief Medical Officer, effective June 1, 2022. "We are excited to appoint Dr. Monson as

    6/1/22 7:00:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Cancer, Ltd. Appoints Susan Howell Jones, CPA as Chief Financial Officer

    HAMILTON, Bermuda, May 17, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ:XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced the appointment of Susan Howell Jones, CPA as Chief Financial Officer. Ms. Jones joins Beyond Cancer™ with over 30 years of international and operational financial leadership experience, including 20 years within the bioscience sector of BASF, a globally recognized chemical company. In her role as Senior Manager of Operational Accounting she was a key member of the implementation team responsible for the $4B acquisition of American Cyanamid. Follow

    5/17/22 7:00:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air® Expands Leadership Team with the Appointment of Dr. Andrew Colin to Chief Medical Officer

    Dr. Colin brings four decades of clinical experience in pediatric pulmonology to Beyond Air, with research spanning respiratory physiology, Cystic Fibrosis, and lung infections culminating in over 120 peer-reviewed publications and 250 global lectures As a board-certified pediatric pulmonologist, Dr. Colin has been an active member of Beyond Air's Scientific Advisory Board since 2013 Dr. Colin has participated in over 20 clinical trials, including studies sponsored by the National Institutes of Health, Genentech, GlaxoSmithKline, and the Cystic Fibrosis Foundation's Therapeutic Development Network GARDEN CITY, N.Y., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a c

    12/1/21 8:00:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Beyond Air Inc.

    SC 13G/A - Beyond Air, Inc. (0001641631) (Subject)

    10/9/24 1:35:29 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Beyond Air Inc.

    SC 13G - Beyond Air, Inc. (0001641631) (Subject)

    10/3/24 3:09:56 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Beyond Air Inc.

    SC 13G - Beyond Air, Inc. (0001641631) (Subject)

    3/7/24 12:29:51 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Financials

    Live finance-specific insights

    View All

    Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast

    GARDEN CITY, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced that it plans to report the financial results for the second quarter of its fiscal year 2025 ended September 30, 2024 on Monday, November 11, 2024 after the market closes. Conference Call & WebcastMonday, November 11th @ 4:30 PM ETDomestic: 1-877-407-0784International: 1-201-689-8560Conference ID: 13749670Webcast: A webcast of the live conference call can be accessed by visiting the Eve

    10/29/24 4:22:08 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2022

    LungFit® PH received FDA approval for the treatment of term and near-term neonates with hypoxic respiratory failure on June 28, 2022 and the first phase of U.S. commercial launch has begun Presented positive data for high-concentration nitric oxide (NO) with LungFit® PRO in hospitalized patients with community-acquired viral pneumonia, including COVID-19, at ECCMID 2022 Presented positive long-term safety data for high-concentration NO at PAS 2022 in infants hospitalized with bronchiolitis Presented positive updated interim data from the ongoing at-home LungFit® GO pilot study for nontuberculous mycobacterial lung disease at ATS 2022 Patient screening has begun for the Phase I trial of

    6/28/22 4:10:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air® Announces Fiscal Year End 2022 Financial Results Conference Call and Webcast Moved to Tuesday, June 28th

    GARDEN CITY, New York, June 14, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that it has rescheduled the reporting of the financial results for its fiscal fourth quarter and year ended March 31, 2022 to Tuesday, June 28, 2022. The Company's management team will also host its quarterly conference call and webcast at 4

    6/14/22 4:30:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care